Navigation Links
Welch Foundation honors Orth as 'rising star' in chemistry
Date:2/3/2010

DALLAS Feb. 3, 2010 Dr. Kim Orth, associate professor of molecular biology at UT Southwestern Medical Center, was honored today with the 2010 Norman Hackerman Award in Chemical Research for pioneering work focusing on the mechanisms bacteria use to cause disease.

The Houston-based Welch Foundation, one of the nation's oldest and largest sources of private funding for basic research in chemistry, presents the award annually to honor up-and-coming scientists at Texas institutions. Recipients are recognized for expanding the frontiers of chemistry through their innovative research.

First bestowed in 2002, the award pays tribute to the late Norman Hackerman, a noted scientist and longtime chairman of the foundation's scientific advisory board. At a luncheon on the UT Southwestern campus, Dr. Orth received the $100,000 award and a crystal sculpture.

Dr. Orth has discovered new mechanisms by which invading bacteria hijack and deregulate a cell's signaling systems, cutting off the cell's ability to communicate with other immune-system cells that are needed to fight off disease. Dr. Orth's studies of these mechanisms have important implications in medicine, especially in understanding and potentially treating infectious diseases and immune-related diseases.

"Kim Orth is an original and creative biochemist and a tribute to our institution," said Dr. Daniel K. Podolsky, UT Southwestern president. "Her discovery of novel chemical modifications of proteins by bacteria that enter and kill cells is an important achievement. The groundbreaking advances made by her laboratory provide the foundation for a better understanding of many significant infectious diseases."

With the addition of Dr. Orth, four of the nine Hackerman Award recipients have been UT Southwestern faculty members. Other winners from the medical center are Dr. Xiaodong Wang, professor of biochemistry, in 2003; Dr. Zhijian "James" Chen, professor of molecular biolo
'/>"/>

Contact: Amanda Siegfried
amanda.siegfried@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
2. David Welch, Friend, Advocate, Inspiration, Loses Courageous Battle to Brain Tumor
3. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
4. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus
5. Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
6. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
7. Welch Allyn Expands Network Services Contract With AT&T
8. Jack Welch to Headline the 8th Annual Lean Six Sigma Healthcare Summit
9. Welch Foundation gives $1.6 million for drug discovery research
10. The National Christian Foundation Offers to Match Gifts to Haiti
11. United Nations Foundation Applauds Bill and Melinda Gates for Their Commitment to Vaccinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 (HealthDay News) -- Arguments between parents may damage ... Parents in more than 200 families were asked ... the end of each day, mothers and fathers rated ... their children. On days when parents reported conflict ... children were also strained, according to the study recently ...
(Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
(Date:8/28/2014)... 28, 2014 Bank lending to the private ... down by 0.13% in real terms, and continuing to fall ... study by UHY, the international accountancy network. , UHY warns ... in particular, the credit crunch lingers on. , UHY says ... last year have been wiped out by inflation. Over the ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy ... groundbreaking brain cancer research projects at the Translational ... has officially received the final regulatory approval from ... enrollment for the trial can begin. , In ... Glioblastoma Trial," TGen and its clinical partners will ...
Breaking Medicine News(10 mins):Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2
... , TARRYTOWN, N.Y., Nov. 24 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009. ... The session may be accessed through the Company,s web ... An archived version of the presentation will be available after ...
... lead to persistent wheezing, study finds , TUESDAY, Nov. ... pollution and indoor endotoxin are at increased risk for ... bacteria believed to trigger an immune response in humans ... College of Medicine researchers found persistent wheezing (an early ...
... less likely to become disabled, study finds , TUESDAY, ... progression of multiple sclerosis, new research suggests. , Belgian ... symptoms between the ages of 22 and 38. , Women ... 34 percent less likely to have the disease progress to ...
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... in China, is proud to announce,that the company received the ... to the top 100 private technology companies in the Asia ... Technology Fast 100 list every year for various,regions, such as ...
... , TEL-AVIV, ... chemicals company, today reported,results for the third quarter and nine ... Financial Results for the Third Quarter , ... $1,347 million, up,24% as compared sequentially with $1,083 million for ...
... ... media to interact with patients and share information about his North Carolina plastic surgery ... ... surgeon Dr. Richard Cummings has joined the popular social networking site Facebook to expand ...
Cached Medicine News:Health News:Traffic, Dust Linked to Asthma in Kids 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 3Health News:Sundia MediTech Receives Red Herring Asia Top 100 Award 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 3Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 4Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 5Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 6Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 7Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 8Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 9Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 10Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 2Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 3
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , August 28, 2014 According ... Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, Printers ... Trends and Forecast, 2014 - 2020" the global radiofrequency ... in 2013 and is expected to grow at a ... an estimated value of USD 5.3 billion in 2020. ...
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... in Asia-Pacific Markets to 2020 - ... Need in Newly Diagnosed and Recurrent ... Glioblastoma Multiforme ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: